Literature DB >> 6609772

Activation of ras genes in human tumors does not affect localization, modification, or nucleotide binding properties of p21.

T Finkel, C J Der, G M Cooper.   

Abstract

A comparison of proteins encoded by normal human ras genes and by mutant rasH or rasK genes activated in human carcinomas revealed no changes in subcellular localization, posttranslational modification, or guanine nucleotide binding associated with activation. Subcellular fractionation indicated that both normal and activated ras proteins were associated exclusively with the membrane fraction. Furthermore, both normal and activated ras proteins exhibited similar degrees of posttranslational acylation. The KD for dGTP binding was 1.0-2.2 X 10(-8) M, with no consistent differences between normal and activated ras proteins. In addition, a survey of 13 possible competing nucleotides revealed no differences in the specificity of nucleotide binding associated with ras gene activation. These results indicate that structural mutations which activate ras gene transforming activity do not alter the protein's known biochemical parameters and in particular do not affect the protein's intrinsic ability to bind guanine nucleotides.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6609772     DOI: 10.1016/0092-8674(84)90310-6

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  40 in total

1.  Biochemical characterization of Artemia ras p21.

Authors:  A Gandarillas; J Renart; M Quintanilla
Journal:  Mol Cell Biochem       Date:  1992-05-13       Impact factor: 3.396

2.  Transfection of insulin-producing cells with a transforming c-Ha-ras oncogene stimulates phospholipase C activity.

Authors:  P O Berggren; A Hallberg; N Welsh; P Arkahammar; T Nilsson; M Welsh
Journal:  Biochem J       Date:  1989-05-01       Impact factor: 3.857

3.  rasH mutants deficient in GTP binding.

Authors:  C J Der; B T Pan; G M Cooper
Journal:  Mol Cell Biol       Date:  1986-09       Impact factor: 4.272

4.  ADP-ribosylation of p21ras and related proteins by Pseudomonas aeruginosa exoenzyme S.

Authors:  J Coburn; D M Gill
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

5.  ras p21 deletion mutants and monoclonal antibodies as tools for localization of regions relevant to p21 function.

Authors:  J C Lacal; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

6.  Characterization of mutations affecting the Escherichia coli essential GTPase era that suppress two temperature-sensitive dnaG alleles.

Authors:  R A Britton; B S Powell; D L Court; J R Lupski
Journal:  J Bacteriol       Date:  1997-07       Impact factor: 3.490

7.  Isolation of ras GTP-binding mutants using an in situ colony-binding assay.

Authors:  L A Feig; B T Pan; T M Roberts; G M Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

8.  Malignant transformation of murine fibroblasts by a human c-Ha-ras-1 oncogene does not require a functional epidermal growth factor receptor.

Authors:  I A McKay; P Malone; C J Marshall; A Hall
Journal:  Mol Cell Biol       Date:  1986-10       Impact factor: 4.272

9.  A product of yeast RAS2 gene is a guanine nucleotide binding protein.

Authors:  F Tamanoi; M Walsh; T Kataoka; M Wigler
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

10.  Suppression of tumorigenicity with continued expression of the c-Ha-ras oncogene in EJ bladder carcinoma-human fibroblast hybrid cells.

Authors:  A G Geiser; C J Der; C J Marshall; E J Stanbridge
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.